Aura Biosciences: A Pivotal Trial Engineered With Room To Spare

What happened: A Seeking Alpha analyst outlined a bullish case for Aura Biosciences (AURA), citing its bel-sar program for early choroidal melanoma, a strategic refocus on ocular oncology, a leadership overhaul, and a workforce reduction. Key numbers: Cash position of $323.8 million as of June 2026, expected to fund operations into 1H 2029. Pivotal Phase 3 data expected in 2027. Why it matters: The analyst argues the cash position removes near-term financing risk ahead of the binary readout, and that AURA trades near cash value, undervaluing its late-stage asset and trial design.

A Seeking Alpha analyst outlined a bullish case for Aura Biosciences (AURA), citing its bel-sar program for early choroidal melanoma, a strategic refocus on ocular oncology, a leadership overhaul, and a workforce reduction.

The analyst argues the cash position removes near-term financing risk ahead of the binary readout, and that AURA trades near cash value, undervaluing its late-stage asset and trial design.